金属硫蛋白 - 潜伏膜蛋白融合基因的体外转录调控

ＥＢ病毒（ＥＢＶ）是一种与地区性伯基特氏淋巴瘤、鼻咽癌、何杰金氏病等多种人体肿瘤有关的疱疹病毒．已往的研究表明,潜伏膜蛋白（ＬＭＰ）基因是ＥＢＶ最可能的致瘤基因．为制备ＬＭＰ基因转基因小鼠,探讨ＬＭＰ的体内致瘤作用,首先构建了含鼠金属硫蛋白－１（ＭＴ－１）基因调控区和ＬＭＰ基因编码区的ｐＢＲ３２２－ＭＴ－ＬＭＰ质粒,并用电击法将该质粒与ｐＫＪ１－Ｎｅｏ质粒共转染人胃癌细胞株ＭＧＣ,对ＭＴ－ＬＭＰ基因在转染细胞中的整合、转录情况及重金属镉和镍对该融合基因的转录调控进行了研究．结果表明：（１）两质粒共转染效率为８６．７％;（２）ＰＣＲ和Ｓｏｕｔｈｅｒｎ杂交分析显示,完整的ＭＴ－ＬＭＰ基因已整合入转染的ＭＧＣ细胞基因组,且在不同的转染细胞克隆中,ＭＴ－ＬＭＰ基因整合的方式及拷贝数不同,拷贝数从１到１９不等;（３）ＲＴ－ＰＣＲ和Ｎｏｒｔｈｅｒｎ杂交分析证实,ＭＴ－ＬＭＰ基因不仅在转染的ＭＧＣ中能够转录,而且在１０μｍｏｌ／Ｌ镉诱导下,ＭＴ－ＬＭＰ基因转录增强,平均增高约１．４倍．结果说明,在ＭＴ－１基因调控区指导下,ＬＭＰ基因不但有ｍＲＮＡ水平的表达,而且其表达受重金属镉的调控,上述结果为制备ＭＴ－ＬＭＰ转基因小鼠     

用核酸免疫技术制备抗丙肝病毒C区单克隆抗体

用丙肝病毒Ｃ＋Ｅ１区真核表达质粒ｐｃＤＮＡ－ＨＣＶ／Ｃ＋Ｅ１按４００ｕｇ／只剂量免疫ＢＡＬＢ／Ｃ小鼠,１４周后同一剂量再加强免疫一次。加强免疫后２周,在５０％ＰＥＧ１４５０介导下将脾细胞与ＳＰ２／０小鼠骨髓瘤细胞（５１）融合。实验结果融合率达５４．３％（３１３／５７６）。阳性率为５．４％（１７”３１３）。克隆化后得到６株稳定分泌抗丙肝病毒Ｃ区单克隆抗体杂交瘤细胞株。这６株杂交瘤均产生ＩｇＭ抗体,接种ＢＡＬＢ／Ｃ小鼠后产生腹水的效价为１６４－１３２０（ＥＬＩＳＡ）。     

用单克隆抗体作芜菁花叶病毒不同分离物外壳蛋白抗原结构的比较研究

用芜菁花叶病毒辽宁分离物（ＴｕＭＶ－ＬＮ）,山东分离物（ＴｕＭＶ－ＳＤ）和榨菜分离物（ＴｕＭＶ－ＺＣ）作抗原,分别免疫ＢＡＬＢ／ｃ小鼠,经脾细胞与ＳＰ２／Ｏ－Ａｇ１４骨髓细胞融合,共获得７个单克隆抗体分泌细胞株,为研究３个分离物的抗原差异,用胰蛋白酶消化ＴｕＭＶ的外壳蛋白（ＣＰ）。分别形成４、２和１条降解带,经ＳＤＳ－１５％ＰＡＧＥ后,转移至硝酸纤维薄膜上,用３个分离物的抗血清和７种单隆抗体分别做     

细胞松弛素B促微丝解聚对DNA合成的作用

利用微丝（ＭＦ）解聚药物细胞松弛素Ｂ（ＣＢ）处理Ｇ０期小鼠Ｃ３Ｈ１０Ｔ１／２成纤维细胞,对Ｇ０至Ｓ期ＤＮＡ合成,胸腺嘧啶核苷激酶（ＴＫ）活性、ＴＫ基因表达、钙调素（ＣａＭ）水平和一些细胞周期早期基因的表达进行了观察。Ｇ０期细胞经３ｍｇ／ＬＣＢ处理２ｈ,促ＭＦ解聚增强了血清对Ｓ期细胞ＴＫ活性、ＴＫ基因表达和ＤＮＡ合成的刺激作用,并促进细胞提前进入Ｓ期。血清刺激Ｇ０期细胞进入晚Ｇ１期和Ｓ期时,ＣａＭ     

贵州桂花净油的化学成分

贵州桂花净油的化学成分巫华美１陈训１何香银１余珍２丁靖垲２（１贵州省生物研究所,贵阳５５０００９）（２中国科学院昆明植物研究所,昆明６５０２０４）ＴＨＥＣＨＥＭＩＣＡＬＣＯＮＳＴＩＴＵＥＮＴＳＯＦＴＨＥＡＢＳＯＬＵＴＥＯＩＬＳＦＲＯＭＯＳＭＡＮＴＨＵ...     

几种克服昆明小鼠2一细胞胚胎发育阻滞的培养液研究

比较了几种培养液对克服昆明小鼠胚胎２－细胞发育阻滞的效果。实验１的结果表明，在Ｍ１６及ＣＺＢ培养液基础上，加减几种成分得到的改进Ｍ１６培养液（用ｍＭ１６表示）和改进的ＣＺＢ培养液（用ｍＣＺＢ表示）均能有效克服２－细胞阻滞现象。除去Ｍ１６和ＣＺＢ培养液中的葡萄糖和磷酸盐后添加５．５５ｍｍｏｌ／Ｌ牛磺酸、１００或１１０μｍｏｌ／Ｌ ＥＤＴＡ、２ｍｍｏｌ／Ｌ谷氨酰胺和２％必需氨基酸（ＥＡＡ）及１％非必需     

乙肝病毒核衣壳启动子内三链DNA的形成

用电泳迁移分析方法研究了２１ｎｔ脱氧寡核苷酸Ｇ３ＴＧ２ＴＧＴ２Ｇ５ＴＧ２ＴＧＴ（ＣＰ１）与１２９ｂｐ的乙肝病毒（ＨＢＶ）核衣壳启动子（Ｃｐ）片段内一位点结合形成的三链ＤＮＡ的特异性及稳定性．在克隆有ＨＢＶ基因组的质粒ｐＣＰ１０的酶切产物中,ＣＰ１仅与含Ｃｐ的１２９ｂｐ片段结合．在２０ｍｍｏｌ／ＬＭｇ２＋溶液中其解离常数（Ｋｄ）为１．４×１０－７ｍｏｌ／Ｌ．不同离子稳定三链ＤＮＡ的效果依次为ｓｐ４＋（精胺）＞Ｍｇ２＋＞Ｚｎ２＋＞Ｎａ＋＞Ｋ＋,离子之间存在相互竞争作用．比ＣＰ１多一误配碱基的脱氧寡核苷酸Ｇ２ＴＧ２ＴＧＴＧ３ＴＧ２ＴＧ２ＴＧ２Ｔ（ＣＰ２）在２０ｍｍｏｌ／ＬＭｇ２＋溶液中与Ｃｐ结合的Ｋｄ值约为ＣＰ１的１／７,而在６０ｍｍｏｌ／ＬＫ＋或５ｍｍｏｌ／ＬＺｎ２＋溶液中检测不到它与Ｃｐ的结合,这进一步显示了三链ＤＮＡ形成的特异性．细胞的生理离子浓度被认为是：Ｓｐ４＋１ｍｍｏｌ／Ｌ,Ｍｇ２＋１０ｍｍｏｌ／Ｌ,Ｋ＋１４０ｍｍｏｌ／Ｌ,因此,ＣＰ１在细胞内将能特异地与Ｃｐ结合并具有较好的稳定性．     

层粘连蛋白受体单克隆抗体抗原性质的鉴定

层粘连蛋白受体（ＬＮ－Ｒ）在癌细胞转移中具有重要作用。ＬＮ－Ｒ的单克隆抗体对于癌转移的基础研究及诊治应用都具有重要意义。本文旨在确定来自人肺巨细胞癌（ＰＧ）细胞ＬＮ－Ｒ的一种单克隆抗体（ＭｃＢ１）的抗原性质。经纯化的ＭｃＢ１能与完整细胞表面、细胞质膜提取物及纯化的ＬＮ－Ｒ制品特异性结合。实验证明经亲和层析纯化的ＬＮ－Ｒ制品中含有膜糖脂,用ＳＤＳ－ＰＡＧＥ及转移电泳将其所复合的膜脂去除后,仍具有与ＭｃＢ１结合的活性,表明此ＭｃＢ１所针对的抗原与其复合的膜糖脂无关。将含ＬＮ－Ｒ的细胞膜提取物经ＰｒｏｎａｓｅＥ消化后,用ＳｅｐｈａｄｅｘＧ５０分离出的糖肽具有与ＭｃＢ１结合的活性,而不含糖的肽则无此活性。含ＬＮ－Ｒ的细胞膜提取物经高碘酸氧化不同时间,其与ＭｃＢ１结合的活性随氧化时间的延长而逐渐减弱乃至完全丧失;而经还原性烷基化反应的ＬＮ－Ｒ仍保持了与ＭｃＢ１结合的活性。用衣霉素（ＴＭ）处理细胞,细胞则丧失了与ＭｃＢ１结合的能力。以上几方面的结果一致证明此ＭｃＢ１的抗原表位确为ＬＮ－Ｒ的糖链部分。     

用T-A载体克隆技术构建丙肝病毒C+E1区真核表达质粒pSVL-HCV/C+E1

用ＢａｍＨＩ和ＨｉｎｄＩＩ将丙肝病毒Ｃ＋Ｅ１ＤＮＡ片段从其克隆载体ｐＧＥＭ３ｚｆ－ＨＣＶ／Ｃ＋Ｅ１上切下,经Ｔａｑ酶补齐３’末端后插入到载体ｐＳＶＬ－Ｔ中,构建成丙肝病毒Ｃ＋Ｅ１真核表达载体ｐＳＶＬ－ＨＣＶ／Ｃ＋Ｅ１。本实验中重组效率达６４．７％（１１／１７）,正向插入为５０％（２／４）。     

Ⅱ型糖尿病患者红细胞膜葡萄糖运输特性研究

红细胞葡萄糖运输的温度依赖性研究结果表明,Ⅱ型糖尿病患者的葡萄９糖输入的活化能比正常增大约３０％,这和患者葡萄糖输入速率减小的结果相一致。但葡萄糖跨膜输出的活化能没有显著变化。驿在红细胞葡萄糖转运蛋白（ＧＬＵＴ１）内侧特异结合的细胞松弛素Ｂ（ＣＢ）的抑制效应研究结果表明,糖尿病人的ＣＢ抑制常数无明显变化。结合以产用根互素抑制剂的实验,表明２型糖尿病患者红细胞膜上ＧＬＵＴ１很可能发生了结构的变化。发     

Cytologic and immunocytologic studies of peripheral T-cell lymphomas

Lymph node aspirates from 18 peripheral T-cell lymphomas (PTLs) were analyzed. Cytologic and immunocytologic studies were performed on Cytospin preparations using the alkaline phosphatase-antialkaline phosphatase method with a panel of monoclonal antibodies (CD3, CD4, CD8, CD19 and CD30). The cytologic diagnosis was confirmed by histologic investigation. Nine lymph node aspirates from patients with Lennert's lymphoma, angioimmunoblastic (AILD)-type PTL and pleomorphic small-cell-type PTL were composed predominantly of small-to-intermediate-sized lymphocytes. An admixture of plasma cells, eosinophils, neutrophils, lymphocytes with an irregular nucleus, granula in the cytoplasm or abundant cytoplasm was also seen. Nine lymph node aspirates from patients with T-immunoblastic lymphoma, pleomorphic large-cell-type PTL and large-cell anaplastic (Ki-1+) lymphoma showed marked cytologic heterogeneity. Immunocytologic investigation of the aspirates using the antibodies CD3, CD4, CD8, CD19 and CD30 was helpful for the differentiation of PTLs from reactive lymphadenopathy and other malignant lymphomas. A strong predominance of CD3+ cells was found in only seven cases. The aspirates expressed a helper/inducer phenotype in 11 cases and a suppressor/cytotoxic phenotype in 4 cases. A T-cell phenotype not corresponding to the normal T-cell phenotype was found in nine cases. In 15 of the 18 cases, the number of CD19+ cells was found to be less than 15%. The large cells of the large-cell anaplastic (Ki-1+) lymphoma expressed the antigens CD30 and CD45 and were negative for CD15. These findings indicate that immunocytologic studies can be used in improving the cytologic diagnosis of PTLs.     

Expression of HLA-DR, MB, MT and SB antigens on human mononuclear cells: identification of two phenotypically distinct monocyte populations

The expression of HLA-DR, SB, MB, and MT antigens in different populations of human mononuclear cells was investigated with the use of monoclonal antibodies that recognize distinct human Ia-like antigens. Our results indicate that in man, as previously reported in other species, two phenotypically distinct populations of monocytes or macrophages can be identified on the basis of expression of Class II MHC antigens. Virtually all circulating monocytes displayed determinants associated with HLA-DR, SB, and MT. In addition, a subpopulation of human monocytes expressed MB/DS-associated antigens, as detected with monoclonal antibodies specific for MB1, MB3, and DS-framework determinants. Most B lymphocytes expressed antigens associated with HLA-DR, and the specificities SB2, SB3, MB1, MB3, MT2, and MT3 were also present. Resting T lymphocytes were unreactive with antibodies that recognize all of the Class II MHC antigens tested. T lymphocytes activated by soluble antigen or alloantigens, and expanded in culture, expressed DR, SB, MB, and MT. The majority of the MB/DS+ cells present in the adherent population were monocytes, because they were phagocytic and had the monocyte-specific marker 63D3. The rest of the cells were not identified. They are likely to include mostly B lymphocytes. The presence of other cells, such as dendritic cells, in this subset needs to be determined.     

Phenotypic drift and clonal variation in differentiation antigen expression on AKR T-cell lymphoma lines grown in vitro

AKR T-cell lymphomas were adapted to tissue culture and analyzed for reactivity with monoclonal antibodies against Thy-1, Ly-1, Ly-2, Ly-5, and H-2K differentiation antigens to determine whether the original phenotype was maintained after adaptation to in vitro culture. Ly-1 and Ly-2 antigens were lost on the majority of lymphomas early in culture and the expression of other lymphocyte differentiation antigens fluctuated when the cell lines were reanalyzed at various time intervals. In addition, the T-lymphoma lines were cloned and the clonal progeny compared with each other and the parent cell lines for differentiation antigen expression. The results demonstrated marked intratumor heterogeneity with respect to antigenic profile. In vivo passage of the cell lines revealed that expression of various antigens was modified after transplantation suggesting that these lymphomas may be susceptible to microenvironmental influences effecting phenotypic alterations. Potential mechanisms contributing to the observed variations in antigenic phenotype on the cultured AKR T-lymphoma lines are discussed.     

A new monoclonal anti-CD3epsilon antibody reactive on paraffin sections.

We generated a new monoclonal antibody (MAb), F7.2.38, by immunizing mice with CD3varepsilongammadelta/CD3omega complexes purified from human T-cells by OKT3 MAb-Sepharose affinity chromatography. Immunoprecipitation experiments and Western blotting analysis showed that MAb F7.2.38 recognized the CD3varepsilon chain in CD3varepsilon cDNA-transfected FOX B-cells and in various T-cell lines. Using flow cytometry on permeabilized or intact cells, the epitope was found to be located in the cytoplasmic tail of the CD3varepsilon chain. Immunohistochemical staining on paraffin-embedded sections showed that the reactivity of MAb F7.2.38 was comparable to that of the commercially available anti-CD3varepsilon polyclonal antibody. Of the 52 well-characterized T-cell lymphomas, 41 were positive for F7. 2.38 (79%), whereas all 37 B-cell lymphomas and 69 non-lymphoid tumors were unreactive. This new anti-CD3varepsilon antibody would be particularly useful for phenotyping T-cell lymphomas on routinely processed paraffin-embedded tissue sections.     

Analysis of Epstein-Barr viral genomes in lymphoid malignancy using Southern blotting, polymerase chain reaction and in situ hybridization

109 malignant lymphomas were surveyed by Southern blot analysis and polymerase chain reaction (PCR) for Epstein-Barr virus (EBV) DNA and compared with 16 examples of non-neoplastic lymphadenopathy and 4 normal thymuses. In specimens positive by the method of Southern and PCR, in situ hybridization studies were performed on formalin-fixed, paraffin-embedded sections. By Southern blot analysis, two of seven Hodgkin's disease samples (29%) (one of mixed cellularity and the other of lymphocyte predominance type), three of 56 B-cell lymphomas (5.6%) and five of 46 T-cell lymphomas (11%) demonstrated EBV DNA. However, the 16 examples of lymphadenitis and the 4 normal thymuses showed no EBV DNA. With PCR, EBV DNA was identified in one B-cell lymphoma, nine T-cell lymphomas, ten lymphadenitis specimens and two of the normal thymus, in addition to the positive specimens determined by the Southern blotting method. These results indicate that the presence of EBV DNA is not related to lymphoid malignancy, but enhancement of the DNA is demonstrated in some neoplastic conditions. By in situ hybridization, EBV genomes were not detected in all PCR-positive cases, but only in those positive by Southern blot analysis.     

Analysis of proliferating cell fraction determined by monoclonal antibody to M1-subunit ribonucleotide reductase and Ki-67 in relation to p53 protein expression in fine-needle aspirates from non-Hodgkin''s lymphomas

The purpose of this study was to analyse the proliferative fraction with the monoclonal antibody M1-R-R to M1-subunit ribonucleotide reductase and with MIB-1 to Ki-67 antigen in relation to p53 protein expression in fine needle aspirates from B-cell non-Hodgkin's lymphomas. One hundred and thirty-seven cases, previously diagnosed and sub-typed according to the Kiel classification and characterized by immunophenotyping, were included in the study. The M-1 subunit ribonucleotide reductase (M1-R-R), Ki-67 and p53 antigens were detected using monoclonal antibodies on stored cytospin preparations. There was a good correlation (r = 0.72) between Ki-67 and M1-R-R positive cell fraction in both high and low grade lymphomas. High-grade lymphomas had a median percentage of M1-R-R/MIB-1 positive cells of 53.0/73.0 for lymphoblastic, 61.0/52.0 for immunoblastic and 33.5/41.0 for centroblastic lymphomas, respectively. In low grade lymphomas figures of median percentage of M1-R-R/MIB-1 were 9.0/15.0 for centroblastic/centrocytic, 11.0/9.5 for chronic lymphocytic leukaemia, 16.0/27.0 for centrocytic and 12.0/9.0 for immunocytomas, respectively. The median percentages of M1-R-R/MIB-1 for high and low grade lymphomas were 37.0/50.5 and 11.0/12.0, respectively. In the p53 positive cases the proliferation rate as measured by staining for M1-R-R and MIB-1 was higher than in p53 negative cases, but the difference was not statistically significant. The results show that cytospin material obtained by fine needle aspiration and stored at -70 degrees C for years can be used reliably for both peroxidase-avidin-biotin and three-step alkaline phosphatase immunocytochemical staining. In addition, proliferation fraction determined by M1-R-R monoclonal antibody staining correlates well with that measured by an established marker for cell proliferation, the Ki-67 antibody. However, the proliferation fraction as measured by the two antibodies differs in the various subtypes of non-Hodgkin's lymphoma which indicates that they may contribute different prognostic information.     

Antigen retrieval in cryostat tissue sections and cultured cells by treatment with sodium dodecyl sulfate (SDS)

A simple method for antigen retrieval in tissue sections and cell cultures is described. Because many antibodies recognize denatured proteins on western blots, but are poorly reactive by immunocytochemistry, the effect of applying sodium dodecyl sulfate (SDS) to cryostat sections of tissues and to cell cultures prior to immunostaining was examined. In many cases, a 5-min pretreatment with 1% SDS produced a dramatic increase in staining intensity by indirect immunofluorescence. Among the antibodies tested that showed a positive effect of SDS were an anti-Na/K-ATPase monoclonal antibody, an anti-AE1/2 anion exchanger polyclonal antipeptide antibody, a monoclonal anti-caveolin antibody, and an anti-rab4 monoclonal antibody. In other cases, including antibodies against gp330, aquaporin 1, and aquaporin 2, no effect of SDS was detected. The results show that SDS treatment can be used as a simple method of antigen retrieval in cryostat sections and on cultured cells. In some cases, antigens were not detectable without pretreatment with SDS.     

Diagnostic utility of α-methylacyl CoA racemase (P504S) & HMWCK in morphologically difficult prostate cancer

The epidermal growth factor receptor (EGFR) family, consisting of four tyrosine kinase receptors, c-erbB1-4, seems to be influential in gliomagenesis. The aim of this study was to investigate EGFR gene amplification and expression of c-erbB1-4 receptor proteins in human anaplastic astrocytomas. Formalin-fixed and paraffin-embedded sections from 31 cases were investigated by standard immunohistochemical procedures for expression of c-erbB1-4 receptor proteins using commercial antibodies. EGFR gene amplification was studied by fluorescence in situ hybridization using paraffin-embedded tissues. Two monoclonal antibodies, NCL-EGFR-384 and NCL-EGFR, were used for EGFR detection and they displayed positive immunoreactivity in 97% and 71%, respectively. For c-erbB2 detection three monoclonal antibodies, CB11, 3B5, and 5A2, were applied and they displayed positive immunoreactivity in 45%, 100%, and 52%, respectively. Positive immunostaining for c-erbB3 and c-erbB4 was encountered in 97% and 74%, respectively. The EGFR gene was amplified in 9 out of 31 tumors (29%). After adjusting for age, Karnofsky performance status, and extent of surgical resection, Cox multiple regression analysis with overall survival as the dependent variable revealed that c-erbB2 overexpression detected by the monoclonal antibody clone CB11 was a statistically significant poor prognostic factor (P = 0.004). This study shows the convenience and feasibility of immunohistochemistry when determining the expression of receptor proteins in tissue sections of human astrocytomas. The synchronous overexpression of c-erbB1-4 proteins in anaplastic astrocytomas supports their role in the pathogenesis of these tumors. Further, c-erbB2 overexpression seems to predict aggressive behaviour.     

Cytomorphology and immunocytochemistry of fine needle aspirates from blastic non-Hodgkin's lymphomas

Fine needle aspirates from 54 consecutive patients with primary or recurrent blastic (high-grade malignant) non-Hodgkin's lymphomas (NHLs) were analyzed by cytomorphology and immunocytochemistry. The cytologic diagnoses induced follicular center-cell-derived (centroblastic or anaplastic centrocytic) lymphoma (31 cases), immunoblastic lymphoma (11 cases), lymphoblastic lymphoma (9 cases) and histiocytic lymphoma (3 cases). Immunocytochemistry showed a B-cell phenotype of the neoplastic lymphocytes in all lymphoblastic lymphomas, 29 follicle center-cell lymphomas and 4 immunoblastic lymphomas. Four of the immunoblastic lymphomas were of T-cell origin while one case was not evaluable due to necrosis. A histiocytic origin was confirmed in two of the three cases that had a cytologic diagnosis of histiocytic lymphoma; the third case was shown by immunocytochemistry to be a true Ki-1-positive large cell lymphoma. Histologic and immunohistochemical analysis were performed on surgical biopsies from 18 patients. The results were in agreement with those on the fine needle aspiration (FNA) material in 14 cases. Three lymphomas could be phenotyped on aspirated material while marker studies on excised material were inconclusive. One lymph node aspirate contained mostly necrotic cells, which were unsatisfactory for adequate immunocytochemistry. However, sections from a removed tonsil from the same patient could be used for conclusive histology and phenotyping. In conclusion, the high diagnostic accuracy of combined cytomorphologic and immunocytochemical assessment of FNA samples validates the use of the technique in the diagnostic work-up of blastic (high-grade malignant) NHLs. In fact, the diagnostic accuracy seems so high that the technique can safely be used in the final diagnosis of blastic NHLs.     

Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells

A group of mAb recognizing the 200- and/or 220-kDa determinants (CD45R) of the leukocyte common Ag such as 2H4, WR16, MD4.3, and SN130 cross-block each other showing that they recognize a closely related epitope. The antibody UCHL1 reacts with a 180-kDa determinant of the leukocyte common Ag and exhibits a reciprocal T subset distribution pattern to the CD45R group. Peripheral blood T cells were 40% positive for UCHL1 and 58 to 65% positive for the CD45R antibodies; less than 1% of cells stained for both. On activation of CD45R+,UCHL1- T cells by PHA, up to 40% of cells became positive for both CD45R and UCHL1 by day 3. By day 7, CD45R+,UCHL1- cells fell from 90 to less than 21% whereas UCHL1+,CD45R- cells rose from 2 to 93%. Conversely, PHA-stimulated UCHL1+,CD45R- cells remained UCHL1+,CD45R- during the 7 days in culture showing that phenotypic change was unidirectional from CD45R+ to UCHL1+. In primary allogeneic mixed lymphocyte reactions, activated CD45R+ T cells also showed a change to UCHL1+. When these cells were rechallenged by the original alloantigen, the UCHL1+ cells showed 7- to 20-fold greater proliferation than the CD45R+ cells on day 3 after rechallenge. The recovery of virtually all alloantigen induced secondary proliferative response in the UCHL1+,CD45R- T cell population suggests that UCHL1 identifies a primed population of T cells which may include memory cells.